DK2016102T3 - Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse - Google Patents

Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse

Info

Publication number
DK2016102T3
DK2016102T3 DK07797329.5T DK07797329T DK2016102T3 DK 2016102 T3 DK2016102 T3 DK 2016102T3 DK 07797329 T DK07797329 T DK 07797329T DK 2016102 T3 DK2016102 T3 DK 2016102T3
Authority
DK
Denmark
Prior art keywords
methods
tcr
chimeric
host
tcrs
Prior art date
Application number
DK07797329.5T
Other languages
English (en)
Inventor
Richard A Morgan
Cyrille J Cohen
Steven A Rosenberg
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2016102(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK2016102T3 publication Critical patent/DK2016102T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07797329.5T 2006-05-03 2007-05-03 Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse DK2016102T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79685306P 2006-05-03 2006-05-03
PCT/US2007/068113 WO2007131092A2 (en) 2006-05-03 2007-05-03 Chimeric t cell receptors and related materials and methods of use

Publications (1)

Publication Number Publication Date
DK2016102T3 true DK2016102T3 (da) 2012-07-02

Family

ID=38668547

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07797329.5T DK2016102T3 (da) 2006-05-03 2007-05-03 Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse

Country Status (9)

Country Link
US (2) US20090304657A1 (da)
EP (1) EP2016102B1 (da)
AT (1) ATE550356T1 (da)
AU (1) AU2007248019B2 (da)
CA (1) CA2651174A1 (da)
DK (1) DK2016102T3 (da)
ES (1) ES2382777T3 (da)
PT (1) PT2016102E (da)
WO (1) WO2007131092A2 (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
DE102006041455B4 (de) * 2006-09-04 2011-07-28 Johannes-Gutenberg-Universität Mainz, 55122 Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
US20110280894A1 (en) * 2008-07-31 2011-11-17 Angela Krackhardt Her2/neu specific t cell receptors
EP2186825A1 (en) * 2008-11-13 2010-05-19 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Human-derived T cell receptors
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US8785601B2 (en) 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
CA2760446C (en) 2009-04-30 2018-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2012040012A1 (en) 2010-09-21 2012-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-ssx-2 t cell receptors and related materials and methods of use
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
RU2661106C2 (ru) 2011-10-28 2018-07-11 Регенерон Фармасьютикалз, Инк. Генетически модифицированные в отношении т-клеточного рецептора мыши
CN110511278A (zh) 2012-05-07 2019-11-29 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
US9487573B2 (en) 2012-05-22 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Murine anti-NY-ESO-1 T cell receptors
WO2014018863A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
EP2932264B1 (en) 2012-12-14 2019-01-30 BioNTech RNA Pharmaceuticals GmbH Novel mhc-independent tumor-associated antigens
US9486475B2 (en) 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
EP2971045B1 (en) * 2013-03-13 2019-06-19 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
CA2906970C (en) 2013-03-21 2021-05-18 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
ES2745472T3 (es) 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
EP3083674B1 (en) * 2013-12-19 2018-10-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Influenza-specific t-cell receptor and its uses in the detection, prevention and/or treatment of influenza
AU2015247727A1 (en) 2014-04-15 2016-11-03 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
PL3149031T3 (pl) * 2014-05-29 2020-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptory limfocytów t przeciwko e7 wirusa brodawczaka ludzkiego 16
CA2948771C (en) 2014-05-30 2023-10-17 Amgen Research (Munich) Gmbh Risk-stratification of b-precursor acute lymphoblastic leukemia patients
AU2015339744B2 (en) * 2014-10-31 2021-03-25 The Trustees Of The University Of Pennsylvania Altering gene expression in CART cells and uses thereof
HRP20231039T1 (hr) 2015-04-06 2023-12-22 Regeneron Pharmaceuticals, Inc. Imunosni odgovori posredovani humaniziranim t stanicama kod ne-humanih životinja
WO2016193300A1 (en) * 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
NZ737400A (en) 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
KR101794304B1 (ko) * 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
EP3347374A1 (en) * 2015-09-09 2018-07-18 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
DK3365364T3 (da) * 2015-10-23 2024-05-06 Eureka Therapeutics Inc Kimære antistof/T-celle-receptorkonstruktioner og anvendelser deraf
CN106632660B (zh) * 2015-11-04 2021-01-29 广东香雪精准医疗技术有限公司 识别ny-eso-1抗原短肽的tcr
KR20200100858A (ko) 2015-12-23 2020-08-26 메디진 이뮤노테라피스 게엠바하 수지상 세포 조성물
US11698369B2 (en) 2016-01-12 2023-07-11 Oncotracker, Inc. Methods for monitoring immune status of a subject
EP3448882B1 (en) 2016-04-26 2021-11-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-kk-lc-1 t cell receptors
JP2019517499A (ja) 2016-06-02 2019-06-24 イムノコア リミテッド ｇｐ１００特異的ＴＣＲ−抗ＣＤ３ ｓｃＦｖ融合タンパク質の投薬レジメン
EP3579877A4 (en) * 2017-02-09 2020-12-09 The Regents of The University of California CHEMERIC T-LYMPHOCYTE ANTIGENIC RECEPTORS AND METHODS OF USE
SG11201909541WA (en) 2017-04-26 2019-11-28 Eureka Therapeutics Inc Chimeric antibody/t-cell receptor constructs and uses thereof
KR20200006985A (ko) 2017-05-12 2020-01-21 오거스타 유니버시티 리서치 인스티튜트, 인크. 인간 알파 태아단백-특이적 t 세포 수용체 및 이의 용도
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
WO2019060425A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
EP3692140B1 (en) * 2017-10-05 2023-07-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods for selectively expanding cells expressing a tcr with a murine constant region
JP2021500875A (ja) * 2017-10-06 2021-01-14 オスロ ウニヴェルスィテーツスィーケフース ハーエフＯｓｌｏ Ｕｎｉｖｅｒｓｉｔｅｔｓｓｙｋｅｈｕｓ Ｈｆ キメラ抗原受容体
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
KR20190076297A (ko) 2017-12-22 2019-07-02 (주)메디톡스 Mart-1 특이적 t 세포 수용체 및 이의 용도
EP3749770A1 (en) 2018-02-09 2020-12-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
US20210147871A1 (en) 2018-04-12 2021-05-20 Umoja Biopharma, Inc. Viral vectors and packaging cell lines
WO2019204683A1 (en) 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
SG11202012339WA (en) * 2018-07-13 2021-01-28 Nanjing Legend Biotech Co Ltd Co-receptor systems for treating infectious diseases
CN110818802B (zh) * 2018-08-08 2022-02-08 华夏英泰（北京）生物技术有限公司 一种嵌合t细胞受体star及其应用
WO2020106992A1 (en) 2018-11-21 2020-05-28 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
KR20200068263A (ko) 2018-12-05 2020-06-15 (주)메디톡스 Ny-eso-1 특이적 t 세포 수용체 및 이의 용도
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113329792A (zh) 2019-02-15 2021-08-31 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020201527A1 (en) * 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
MX2022011080A (es) 2020-03-10 2023-01-04 Massachusetts Inst Technology Metodos para generar celulas nk de tipo memoria modificadas y composiciones de las mismas.
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2021341969A1 (en) 2020-09-08 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
US20240018210A1 (en) 2020-11-13 2024-01-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN117980326A (zh) 2021-07-14 2024-05-03 2赛文缇生物公司 与来自抗体的结合结构域融合的经工程化的t细胞受体
WO2023002204A1 (en) * 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023130040A2 (en) 2021-12-31 2023-07-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell therapy with vaccination as a combination immunotherapy against cancer
WO2023196996A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407221B1 (en) * 1990-12-14 2002-06-18 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
ATE145428T1 (de) * 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
ATE546457T1 (de) * 1999-03-19 2012-03-15 Waldemar Priebe Verfahren und zusammensetzungen zur herstellung von c-3' und c-4' -anthracyclin antibiotika
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances

Also Published As

Publication number Publication date
AU2007248019A1 (en) 2007-11-15
CA2651174A1 (en) 2007-11-15
ATE550356T1 (de) 2012-04-15
US20090304657A1 (en) 2009-12-10
EP2016102A2 (en) 2009-01-21
EP2016102B1 (en) 2012-03-21
PT2016102E (pt) 2012-05-15
AU2007248019B2 (en) 2012-10-11
WO2007131092A2 (en) 2007-11-15
ES2382777T3 (es) 2012-06-13
US20130116167A1 (en) 2013-05-09
WO2007131092A3 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
DK2016102T3 (da) Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse
Larsen et al. The role of IL-33/ST2 pathway in tumorigenesis
WO2004069876A3 (en) Trimeric polypeptide construct to induce an enduring t cell response
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
UA107921C2 (en) Variants of polypeptide of receptor ivr activin and their use
AR064639A1 (es) Gen de bacillus thuringiensis con actividad contra lepidopteros
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
Ng et al. Multiple interactions between cytoplasmic domains regulate slow deactivation of Kv11. 1 channels
WO2008089053A3 (en) Gp100-specific t cell receptors and related materials and methods of use
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
WO2008080042A3 (en) Use of long-acting glp-1 receptor agonists to improve insulin sensitivity and lipid profiles
MX2020009371A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
DK1641818T3 (da) Polypeptider der har bindingsaffinitet for HER2
NZ592973A (en) Compositions and methods of using angiopoietin-like 4 protein
MX2015003061A (es) Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
NO20064134L (no) Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav
MX2019002345A (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
BRPI0508068A (pt) moléculas de ácido nucléico isoladas, vetor compreendendo as mesmas, polipeptìdeos isolados e composições compreendendo os mesmos
WO2006128668A3 (en) Coagulation factor x polypeptides with modified activation properties
DK1804835T3 (da) Multimere konstruktioner
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
IN2012DN02981A (da)
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
Maqboul et al. Expression profiles of TRPV1, TRPV4, TLR4 and ERK1/2 in the dorsal root ganglionic neurons of a cancer-induced neuropathy rat model